Ibopamine

Bussmann, W.‐D.; Wienhöfer, K; Frik, R

doi:10.1159/000174452

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In healthy volunteers and patients with or without congestive heart failure, most double-blind studies have shown ibopamine to increase diuresis and in some instances these changes were significant (Bussmann et al 1988;Henwood & Todd 1988). In healthy volunteers and patients with or without congestive heart failure, most double-blind studies have shown ibopamine to increase diuresis and in some instances these changes were significant (Bussmann et al 1988;Henwood & Todd 1988).…”

Section: Renal Effectsmentioning

confidence: 99%

Spencer¹,

Faulds²,

Fitton³

1993

Drugs & Aging

View full text Add to dashboard Cite

Ibopamine is an orally administered dopamine agonist which is rapidly converted to its active metabolite epinine by esterase hydrolysis. Ibopamine acts predominantly as a vasodilator and inhibitor of neuroendocrine activation in congestive heart failure, but also has mild positive inotropic effects at higher doses. The beneficial effects on cardiac and systemic haemodynamic parameters seen in short term studies have been maintained in predominantly noncomparative trials for up to 1 year, and improvements in New York Heart Association (NYHA) functional class and clinical symptoms have been observed in patients with congestive heart failure of varying severity. In double-blind studies conducted in small numbers of patients, the efficacy of ibopamine was comparable to that of digoxin, captopril, enalapril and hydrochlorothiazide. Ibopamine can successfully replace treatment with intravenous dopamine in patients with severe heart failure, and is effective and well tolerated when administered in combination with digoxin, diuretics and/or angiotensin converting enzyme (ACE) inhibitors. Ibopamine has shown no detrimental effects on renal function, few adverse effects on neurohormonal parameters and has demonstrated no significant proarrhythmic properties at therapeutic doses in patients with congestive heart failure. No adverse metabolic effects were observed during ibopamine therapy in patients with diabetes mellitus, nor did ibopamine have detrimental effects in patients with chronic obstructive pulmonary disease. While reliable evidence is required concerning effects on mortality before the role of ibopamine can be clearly defined, the drug appears to be a useful agent for combination with conventional therapies in treating patients with mild to severe congestive heart failure.

show abstract

Section: Renal Effectsmentioning

confidence: 99%

Ibopamine

Spencer¹,

Faulds²,

Fitton³

1993

Drugs & Aging

View full text Add to dashboard Cite

show abstract

Ibopamine-induced reversible leukopenia during treatment for congestive heart failure

Said¹,

Bucx²,

Dankbaar³

et al. 1993

European Heart Journal

View full text Add to dashboard Cite

Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure. Her antecedent medical history included stable, mild renal function impairment, mitral regurgitation, atrial fibrillation, recurrent transient ischaemic attacks and cholelithiasis. The drugs concomitantly used were digoxin, isosorbide dinitrate, frusemide, urapidil and chlorthalidone in conjunction with oral potassium substitution. Upon withdrawal of ibopamine but continuation of all other drugs, the patient recovered from the blood dyscrasia within 5 days and showed resolution of symptoms. Measurements of protected isolation and selective intestinal decontamination were taken. No complications resulting from secondary infection occurred. After withdrawal of ibopamine and under continuation of all other concomitant medications her body weight continued to decrease during the following few days, her symptoms were alleviated and she was discharge to a nursing home.

show abstract

Ibopamine - How Should It Be Used?

Cited by 2 publications

References 10 publications

Ibopamine

Ibopamine

Ibopamine-induced reversible leukopenia during treatment for congestive heart failure

Contact Info

Product

Resources

About